Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit
-- Dr. Rodino-Klapac, a
-- Served as a principal investigator and co-inventor of the micro-dystrophin technology for the gene therapy Duchenne muscular dystrophy (DMD) clinical trial underway by Sarepta and Nationwide Children’s Hospital --
Until her appointment with Sarepta, Dr. Rodino-Klapac was head of the laboratory for gene therapy research for Muscular Dystrophies at Nationwide Children’s Hospital and is renowned for her work in molecular genetics and gene therapy. Her ground-breaking work has involved 11 investigational new drug applications for gene therapy, research resulting in numerous field-advancing peer-reviewed publications, and the advancement of six gene therapy programs from bench to human clinical development.
She was an Associate Professor,
Dr. Rodino-Klapac will retain her position as acting chief scientific officer of
“I could not be prouder to welcome Dr. Rodino-Klapac, a celebrated genetic medicine luminary, to Sarepta and to our mission to improve the lives of those living with neuromuscular conditions. Her appointment to lead our gene therapy division perfectly exemplifies our strategy of quickly becoming among the most meaningful global genetic medicine companies by retaining and nurturing the field’s best and brightest gene therapy and neuromuscular scientists,” said
“Making an impact on the lives of patients affected by muscular dystrophies has been central to my professional work. Sarepta’s RNA platforms and multiple gene therapy programs provide significant opportunity to make a profound difference for patients with neuromuscular diseases,” said Dr. Rodino-Klapac. “I’m excited to join the Sarepta team leading its gene therapy development efforts, and share the organization’s urgency to advance its robust pipeline of potential therapies.”
Dr. Rodino-Klapac is the recipient of numerous awards, including the Forty Under 40 Award by Columbus Business First, and the
Dr. Rodino-Klapac also served as the
This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sarepta’s mission to improve the lives of those living with neuromuscular conditions; Dr.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta’s gene therapy programs may not result in any viable treatments suitable for clinical research or commercialization due to a variety of reasons, including the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates or may never become commercialized products due to other various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and even if Sarepta’s gene therapy programs result in new commercialized products, Sarepta may not achieve any significant revenues from the sale of such products; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended
Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2017 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com.We encourage investors and potential investors to consult our website regularly for important information about us.
Media and Investors:
Source: Sarepta Therapeutics, Inc.
Latest Annual Report( FY 2017 )
Sarepta IR Presentation (December 2017)